Engineers Gate Manager’s Ovid Therapeutics OVID Stock Holding History

Engineers Gate Manager’s Portfolio OVID Stock Details OVID Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-12,549	Closed	-$49K	–	1884
2021 Q2	$49K	Buy	+12,549	New	+$49.5K	﹤0.01%	1546
2021 Q1	–	Sell	-13,000	Closed	-$30K	–	2047
2020 Q4	$30K	Sell	13,000 -10,500	-45%	-$48.9K	﹤0.01%	1646
2020 Q3	$135K	Buy	+23,500	New	+$157K	0.01%	1505

Other funds holding OVID

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Globeflex Capital San Diego, California $661M AUM 50.59% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Engineers Gate Manager's OVID Position: Q3 2021 in Review

Engineers Gate Manager sold out of Ovid Therapeutics (OVID) in Q3 2021, closing a stake of 12,549 shares — an estimated $49K sold.

Engineers Gate Manager first reported a position in OVID in Q3 2020 and held it in 3 quarters. The position peaked at $135K in Q3 2020. 72 funds tracked by Wall St. Rank hold OVID as of Q3 2021.

Engineers Gate Manager reported no remaining Ovid Therapeutics position as of Q3 2021 after selling out during the quarter.
Engineers Gate Manager sold 12,549 Ovid Therapeutics shares in Q3 2021, an estimated $49K.
Engineers Gate Manager first reported a position in Ovid Therapeutics in Q3 2020 and held it in 3 quarters.
Engineers Gate Manager's Ovid Therapeutics position peaked at $135K in Q3 2020.
72 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q3 2021.

Based on Engineers Gate Manager's 13F filing for Q3 2021, filed 15 Nov 2021.